ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: SA-PO457

Coexisting Variations in Complement Regulatory Genes Increase Risk of Relapse in Anti-Factor H (FH) Antibodies Associated Atypical Hemolytic Uremic Syndrome (aHUS)

Session Information

  • Pediatric Nephrology - II
    October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1600 Pediatric Nephrology


  • Khandelwal, Priyanka, All India Institute of Medical Sciences, New Delhi, India
  • Faruq, Mohammed, Institute of Genomics and Integrative Biology, New Delhi, India
  • Puraswani, Mamta, All India Institute of Medical Sciences, New Delhi, India
  • Sinha, Aditi, All India Institute of Medical Sciences, New Delhi, India
  • Bagga, Arvind, All India Institute of Medical Sciences, New Delhi, India

Group or Team Name

  • Indian HUS database

Patients with anti-FH antibodies, comprising one-half of children with aHUS in India, are managed by PEX and immunosuppression (IS). While deficiency of FH related protein-1 (CFHR1) is strongly associated, prevalence of additional variations and their impact on outcomes is unclear.


Of 435 children with anti-FH aHUS in the nationwide database, 93 (21%) were screened by targeted sequencing of 27 genes, comprising full length CFH, CFI, CFB, C3, CD46, THBD, DGKE, coding regions of CFHR1-5, PLG, ADAMTS13 and lectin & terminal pathway. Genotype-phenotype correlation and risk-factors for relapse & adverse outcomes (eGFR <30 mL/min/1.73 m<font size="1">2</font> or death) were evaluated.


Patients aged 9±3 yr had high anti-FH titers (median 4684 AU/ml) that persisted >1000 AU/ml during remission in one-third. At 44-mo follow up, adverse outcome was seen in 20% and relapses in 30% (17% and 30% in database, respectively; P=0.02 and <0.001). Sequencing at mean depth of 123X (96% coverage) showed variants of unknown significance (VUS) in 6.5% (Table). MLPA showed homozygous deletion (90%) or duplication (N=1) of CFHR1. Severity of renal and extrarenal manifestations were independent of genetic variations. Prompt PEX (Hazard ratio, HR=1.03; P=0.009), lower anti-FH titers (HR=1.00; P=0.06) and lower peak creatinine (HR=1.2; P=0.008) were associated with improved outcomes. MASP1 (c.*822C>T) polymorphism protected against relapses (allele frequency relapsers 0.015; non- relapsers 0.11; P=0.02). Maintenance IS (odds ratio, OR=10; P=0.02), no coexisting variations (OR=13; P=0.03); low C3 at onset (OR=5; P=0.03) and MASP1 polymorphism (OR=8; P=0.06) independently reduced the risk of relapses.


Prompt PEX & IS improves long-term outcomes and prevents relapses in patients with anti-FH aHUS. Coexisting variations in regulatory genes might predispose to relapses.

Variant (all heterozygous)PathogenicityAge yrC3 mg/dlAnti-FH AU/mlRelapse, at mo-eGFR & outcome at follow-up
c.148C>G, p.P50A
Pathogenic^4748800One, 24-mo82 at 14 yr,
ambulatory HPT
c.127G>A, p.A43T
Likely pathogenic^64216133One, 6-moESRD
c.685G>A, p.G229R
VUS, rare9894260None89 at 21-mo;
HPT, proteinuria
c.193T>C, p.Y65H
VUS, rare9407956One, 6-mo43 at 11-mo;
c.596C>A, p.A199D
VUS, novel44026741One, 9-mo84 at 44-mo;
HPT, proteinuria
VUS, novel74332152,6 & 24 mo-64 at 66-mo;

^reported functional assay; HPT, hypertension


  • Government Support - Non-U.S.